The U.S. House of Representatives-approved report language, which was secured through the Company's Nexalin America division, includes the following report language under the "Non-Invasive Neurostimulation for Traumatic Brain Injury" section of the bill's report:

"The Committee is aware of emerging research on non-invasive deep brain neurostimulation technologies for the treatment of traumatic brain injury (TBI) and is encouraged by early findings demonstrating potential benefits for veterans with treatment-resistant TBI. The Committee encourages the Department to support additional research evaluating the safety, efficacy, and potential clinical applications of these technologies for veterans experiencing treatment-resistant TBI."

The Fiscal Year 2027 House Military Construction, Veterans Affairs, and Related Agencies Appropriations bill is expected to proceed to a U.S. House-Senate conference following passage of a comparable legislative product expected to emerge from the U.S. Senate. The House's bill includes $945 million for VA Medical Research, an account that supports critical research areas including traumatic brain injury and mental health. The neurostimulation-directive language was one of only a handful of Congressional directives on this account, suggesting a potentially expanded opportunity within the VA for non-invasive deep brain neurostimulation technologies such as Nexalin. The team at Nexalin America believes the Nexalin DIFS™ waveform meets the expectation of the VA's directive for non-invasive deep brain stimulation. Nexalin has recently published several peer-reviewed articles validating its unique frequency based deep brain stimulation technique.

The inclusion of this language finally makes a distinction between traditional stimulation devices currently used in the military and the new Nexalin DIFS™ waveform. Additionally, the language represents the advancement and distinction of Nexalin's new non-invasive deep brain neurostimulation.